We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genedata Forges Alliance with Intellicyt
News

Genedata Forges Alliance with Intellicyt

Genedata Forges Alliance with Intellicyt
News

Genedata Forges Alliance with Intellicyt

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genedata Forges Alliance with Intellicyt "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The firms will integrate Genedata's Screener software with IntelliCyt's iQue Screener system.

The alliance will bring Genedata's highly-scalable data analytics to IntelliCyt's high-throughput flow cytometry capabilities. The iQue Screener can analyze more than 10,000 cells or beads per second, the firm said in a statement, an order of magnitude increase over plate-based systems, with up to 15 parameters per cell.

"Advanced computational analysis solutions are required to handle the quantity and complexity of data obtained in high-throughput flow cytometry experiments in large-scale screening applications," Janette Phi, chief business officer at Albuquerque, New Mexico-based IntelliCyt, said in a statement. "The combined solution of Genedata Screener software and the IntelliCyt iQue Screener platform addresses this unmet industry need. Our solution provides a powerful option for our customers for robust and accurate data analysis across all plates from high-throughput flow cytometry data generated by iQue."

The combined technologies will enable researchers to screen large libraries of drug candidates against suspension cells and multiplex beads in phenotypic drug discovery, antibody screening, immunology, and biomarker research, the firms said.


Advertisement